 Artist: X-Ray Spex: mp3 download Genre(s): Rock: Punk-Rock Discography:  Anthology CD2 Year: 2001 Tracks: 11  Anthology CD1 Year: 2001 Tracks: 26  Germfree Adolescents Year: 1978 Tracks: 16 One of the great English punk bands of the recent '70s, in that obedience is only unitary thing unseasonable with the careers of X-Ray Spex and tether vocalizer Poly Styrene -- they didn't track record enough medicine. Formed in 1976 by schooling friends Marion Elliot (Cinnamene) and Susan Whitby (saxist Lora Logic), X-Ray Spex exploded onto the punk rocker picture with one of the era's majuscule singles, the women's rightist hood rally shout "Oh Bondage, Up Yours." With Logic's adolphe Sax stating the melody semi-tunefully and Jak Airport's guitar laying downward a wash of malformed chords, Styrene's vocal, especially on the chorus, is a curiosity. Along with the former Sex Pistols and Clash singles, this was one of kindling rock rock's great moments. So, overly, was X-Ray Spex's debut LP, Bug Free Adolescents, which was great in cattiness of "Oh Bondage" non organism on it (a place that would be rectified with the 1993 CD reissue). Lora Logic was kaput (to form Essential Logic), simply her substitute, Rudi Thompson, played in as underlying a fashion, merely stayed in tune a small more than. The songs were guitar-driven punk-pop that combined outrage and aggression with a sense of estrangement and disenfranchisement around rearing mercantilism and an progressively unimaginative and hokey world. Styrene's songs were more likely to be about drowning in a sea of corporate-designed consumer fantasies than outright attacks against the political science. This didn't bastardly the songs were whatever less political; they but attacked the zeitgeist from a different vantage point. Tragically, there was no immediate second X-Ray Spex criminal record. But in that location was Poly Styrene's only full-length solo record book, Semitransparency. Abandoning completely the flash guitars of X-Ray Spex, Semitransparency is quiet and jazzy in a way that anticipates the work of Ben Watt and Tracey Thorn in Everything But the Girl. It's a bit of a shock approach later Germ Free Adolescents, merely it's a beautiful album, and Styrene's telling, though not as exciting and disturbed, is often stunning. Consistent with her career up to this point, Poly Styrene dropped out of music completely shortly later on the release of Translucency and joined a London-based Hare Krishna faction. She emerged from "retirement" in 1986 with a wonderful EP titled Gods and Goddesses. In late-2006, the Spex got luxe treatment from Sanctuary Records with the release of Let's Submerge: The Anthology, a two-disc assembling that features pretty much the band's full recorded output and and then some. |
Thursday, 21 August 2008
Download X-Ray Spex mp3
Monday, 11 August 2008
Natalie Cole returns with 'Still Unforgettable'
Natalie Cole [ ] has arrange together a fall circuit to case material from her upcoming album of American standards, "Still Unforgettable."
The Grammy-winning R&B/jazz singer volition spend the month of October performing nearly a dozen shows across the East Coast and into Canada. Her itinerary is included below.
story_top_holder>
"Still Unforgettable," due Sept. 9, is the sequel to 1991's "Unforgettable ... With Love," which sold more than 14 million copies cosmopolitan and earned Cole several Grammy Awards. The rubric track on the latter album is a posthumous duet with Cole's legendary father, Nat King Cole. On the new album, father and daughter reunify for the lead single, "Walkin' My Baby Back Home."
"If there was going to be some other 'duet' with Dad, I felt it should be something more than whimsical, fun and clean," Cole aforementioned in her bio. "At the same time, I was looking for a song that would besides be familiar to a certain type of audience. I remember this is going to work just as well. It's adorable and loving between parent and youngster. It feels like he's right at that place with me. How do you top of the inning that?"
"Still Unforgettable" is Cole's 21st studio effort and marks her first metre in the producer's chair. The set comprises 14 standards, including "Come Rain or Come Shine," "The Best is Yet to Come" and "Nice 'N' Easy," samples of which are streaming at Cole's website.
The new album follows 2006's "Leavin'," which features pop, R&B and rock covers alongside the original tune "5 Minutes Away." Cole's interpretation of Aretha Franklin's "Day Dreaming" on "Leavin'" marked her number one urban/pop single in intimately 16 years and earned her some other Grammy nomination.
The singer's eight-Grammy streak started in 1975 with her debut record album, "Inseparable."
Reports recently revealed that Cole is being treated for Hepatitis C, but the condition is not expected to interfere with her tour plans.
[Note: The next tour dates have been provided by artist and/or tour sources, who verify its accuracy as of the publication time of this level. Changes may occur before go on sale. Check with official artist websites, ticketing sources and venues for late updates.]
October 20087 - Indiana, PA - Fisher Auditorium 9 - N. Bethesda, MD - Music Center at Strathmore 10 - Brooksville, NY - Tiles Center for the Performing Arts 11 - Newport News, VA - Ferguson Center for the Arts Concert Hall12 - Charlottesville, VA - Paramount Theatre 15 - Fort Walton Beach, FL - Emerald Coast CC17 - Birmingham, AL - BJCC Concert Hall 18 - Columbus, GA - RiverCenter 19 - Atlanta, GA - Cobb Energy Performing Arts Centre 22 - Brampton, Ontario - Rose Theatre 23 - Windsor, Ontario - The Colosseum at Caesars Windsor
More info
Wednesday, 6 August 2008
BRIDION(R) (sugammadex) Injection - First And Only Selective Relaxant Binding Agent - Approved In European Union
�Schering-Plough
Corporation (NYSE: SGP) announced that the European Commission (EC)
has approved BRIDION(R) (sugammadex) injection, the first and only
selective relaxant ski binding agent (SRBA) and the first major pharmaceutical
nesthetic
operation or during surgery, grimacing, or nurseling on the endotracheal
tube. In a few individuals, allergic-like reactions (i.e. flushing,
erythematous rash) undermentioned sugammadex were reported.
About ESMERON
ESMERON (rocuronium bromide) is a non-depolarizing muscle relaxant. It
was introduced in Europe 1994 and is one of the nigh widely used muscle
relaxants in the United States, Canada (where it is marketed under the
brand name ZEMURON) and many European countries. It was approved for use in
Japan in July 2007 under the brand cite ESLAX.
For full Prescribing Information please go to http://www.esmeron.com.
About Schering-Plough
Schering-Plough is an innovation-driven, science-centered world health
tending company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and meliorate
lives around the earthly concern. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. Schering-Plough's vision is to "Earn Trust, Every Day"
with the doctors, patients, customers and other stakeholders served by its
colleagues about the world. The ship's company is based in Kenilworth, N.J., USA,
and its Web site is hypertext transfer protocol://www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The info in this press
release includes sure "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the plans for, the potential of and the potential market for
BRIDION. Forward-looking statements relate to expectations or forecasts of
future events. Schering-Plough does not sham the indebtedness to update any
advanced statement. Many factors could cause actual results to
differ materially from Schering-Plough's forward-looking statements,
including market forces, economic factors, product availability, patent and
former intellectual property protection, stream and future branded, generic
or over-the-counter competition, the regulatory march, and whatsoever
developments following regulatory favourable reception, among other uncertainties. For
further details of these and other risks and uncertainties that may encroachment
forward-looking statements, see Schering-Plough's Securities and Exchange
Commission filings, including Item 1A, "Risk Factors" in the company's
first quarter 2008 10-Q.
Schering-Plough Corporation
http://www.schering-plough.com
More info
Corporation (NYSE: SGP) announced that the European Commission (EC)
has approved BRIDION(R) (sugammadex) injection, the first and only
selective relaxant ski binding agent (SRBA) and the first major pharmaceutical
nesthetic
operation or during surgery, grimacing, or nurseling on the endotracheal
tube. In a few individuals, allergic-like reactions (i.e. flushing,
erythematous rash) undermentioned sugammadex were reported.
About ESMERON
ESMERON (rocuronium bromide) is a non-depolarizing muscle relaxant. It
was introduced in Europe 1994 and is one of the nigh widely used muscle
relaxants in the United States, Canada (where it is marketed under the
brand name ZEMURON) and many European countries. It was approved for use in
Japan in July 2007 under the brand cite ESLAX.
For full Prescribing Information please go to http://www.esmeron.com.
About Schering-Plough
Schering-Plough is an innovation-driven, science-centered world health
tending company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and meliorate
lives around the earthly concern. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. Schering-Plough's vision is to "Earn Trust, Every Day"
with the doctors, patients, customers and other stakeholders served by its
colleagues about the world. The ship's company is based in Kenilworth, N.J., USA,
and its Web site is hypertext transfer protocol://www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The info in this press
release includes sure "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the plans for, the potential of and the potential market for
BRIDION. Forward-looking statements relate to expectations or forecasts of
future events. Schering-Plough does not sham the indebtedness to update any
advanced statement. Many factors could cause actual results to
differ materially from Schering-Plough's forward-looking statements,
including market forces, economic factors, product availability, patent and
former intellectual property protection, stream and future branded, generic
or over-the-counter competition, the regulatory march, and whatsoever
developments following regulatory favourable reception, among other uncertainties. For
further details of these and other risks and uncertainties that may encroachment
forward-looking statements, see Schering-Plough's Securities and Exchange
Commission filings, including Item 1A, "Risk Factors" in the company's
first quarter 2008 10-Q.
Schering-Plough Corporation
http://www.schering-plough.com
More info
Subscribe to:
Posts (Atom)